A study published in Nature Medicine found that the recombinant shingles vaccine is associated with a significantly lower risk of dementia compared to the live shingles vaccine. Using a natural experiment created by the rapid transition from the live to the recombinant vaccine in the US, researchers compared dementia risk between vaccine types. They found that the recombinant vaccine was linked to a 17% increase in diagnosis-free time, translating to 164 additional days lived without a dementia diagnosis. The effect was consistent across both men and women, with a greater impact in women. The recombinant vaccine also showed lower dementia risks than influenza and tetanus-diphtheria-pertussis vaccines. The findings were robust across multiple analyses and suggest the need for further research to confirm the protective effects. The study used electronic health records and propensity-score matching to control for confounding factors. While the study is observational, the rapid vaccine transition minimized selection bias. The results support further investigation into the mechanisms behind the protective effect and could inform future randomized control trials. The study highlights the potential public health benefit of the recombinant shingles vaccine in reducing dementia risk.A study published in Nature Medicine found that the recombinant shingles vaccine is associated with a significantly lower risk of dementia compared to the live shingles vaccine. Using a natural experiment created by the rapid transition from the live to the recombinant vaccine in the US, researchers compared dementia risk between vaccine types. They found that the recombinant vaccine was linked to a 17% increase in diagnosis-free time, translating to 164 additional days lived without a dementia diagnosis. The effect was consistent across both men and women, with a greater impact in women. The recombinant vaccine also showed lower dementia risks than influenza and tetanus-diphtheria-pertussis vaccines. The findings were robust across multiple analyses and suggest the need for further research to confirm the protective effects. The study used electronic health records and propensity-score matching to control for confounding factors. While the study is observational, the rapid vaccine transition minimized selection bias. The results support further investigation into the mechanisms behind the protective effect and could inform future randomized control trials. The study highlights the potential public health benefit of the recombinant shingles vaccine in reducing dementia risk.